GenSci Expects Topical Molgramostim Gel Approval in 2007

SHANGHAI, China--(BUSINESS WIRE)--GeneScience Pharmaceuticals Co., Ltd. (GenSci) announced today that the company's new drug, Genfulin™, a topical gel indicated for the treatment of wound healing, is expected to get approval by China's SFDA in early 2007.

The active ingredient in Genfulin™ is molgramostim (human granulocyte-macrophage colony stimulating factor, hGM-CSF [rDNA origin]). GenSci has been the top biopharmaceutical manufacturer for Jintropin™ somatropin (human growth hormone, hGH), Scimax™ filgrastim (human granulocyte colony stimulating factor, G-CSF) and molgramostim in China.

"With the unique innovative formulation, Genfulin™ marks the major step in GenSci's transition to manufacturing biological supergenerics," according to Dr. Lei Jin, CEO of GenSci.

Based on the current indications of molgramostim, Genfulin™ gel was designed for new indications in wound healing with its novel and unique formulation. Most importantly, clinical trials of Genfulin™ have confirmed its efficacy in actively accelerating wound healing, increasing wound tearing-resistance, and reducing, even avoiding, scar proliferation in burn patients. Similar effects have also been observed in chronic ulcer patients, including those with diabetic foot ulcer. Overall, Genfulin™ gel has been shown to improve the quality of wound healing significantly with a good safety profile, according to results obtained from clinical trials.

Genfulin™ gel is applied to wound areas directly in patients with burn, scald or ulcer to speed up the healing. GenSci holds a patent for Genfulin™, which was developed with GenSci's proprietary technology platform by scientists at GenSci.

Genfulin™, Jintropin™, Scimax™ are trademarks of GenSci.